The serum-free selection culture method was applied to generate human placenta maternal-part (choriodecidual membrane) mesenchymal stem cells (pcMSCs), which could be used to cure acute severe injury; pcMSCS could be sub-cultured more than 20-passages thus could make a cell-bank for emergency use; importantly, pcMSCs could not promote tumor growth and sometime could inhibits certain tumors growth.

1.Serum-free selection culture method (2 patents in Taiwan).
2.The cells are no risk for tumor promoting thus can be used systemically in safety.
3.Multi-potency in immunemodulation.
4.Mass-production for the cell in serum-free culture; even after 20-passages, the cells still have multi-potency in immunomodulation and stem cell potentials.
5.Highly safe and effective, suitable for aging groups.

We have successfully generated the clinical grade human pcMSCs with high passage capacity (>20 passages) using novel serum-free selection cultivation. The pcMSC unique characters in stemness stability and free of tumor growth risk highly benefit the future patient affordable clinical allogenic cell therapy, in particular for the systemically safe use of age-related diseases and cancer patients.